Alexion (ALXN) and Portola Pharmaceuticals (PTLA) $1.4bn acquisition information is displayed in the merger details table. An invaluable buyout factsheet for traders and investors looking to trade the merger arbitrage spread.
This deal was successfully consummated on July 2, 2020
Portola Pharmaceuticals (PTLA) Acquisition
Portola Pharmaceuticals (NASDAQ: PTLA) Acquisition - Merger News and Events
The major Alexion (ALXN) and Portola Pharmaceuticals (PTLA) acquisition news updates & events are listed below. A comprehensive data source for traders & investors looking to familiarize themselves with the Alexion (ALXN) merger with Portola Pharmaceuticals (PTLA) and trade the merger arbitrage spread, or for existing shareholders wishing to stay abreast of the latest deal developments. Following the acquisition news and events section, there is an in-depth company profile.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness.
It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.
